Lantern Pharma (LTRN) Total Liabilities (2019 - 2026)

Lantern Pharma (LTRN) has reported Total Liabilities for 8 consecutive years, with $11.8 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities rose 141.32% year-over-year to $11.8 million; the trailing twelve-month figure through Jun 2026 stood at $11.8 million (up 141.32% YoY), and the FY2025 full-year result was $4.5 million, up 2.68% from the prior year.
• Total Liabilities advanced to $11.8 million in Q2 2026 per LTRN's latest filing, from $3.8 million in the prior quarter.
• Across five years, Total Liabilities topped out at $11.8 million in Q2 2026 and bottomed at $2.4 million in Q3 2023.
• Historically, Total Liabilities has averaged $4.2 million across 5 years, with a median of $3.9 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities surged 299.35% in 2022, then slumped 40.3% in 2023.
• Over 5 years, Total Liabilities stood at $2.8 million in 2022, then declined by 2.09% to $2.7 million in 2023, then surged by 60.02% to $4.4 million in 2024, then climbed by 2.68% to $4.5 million in 2025, then soared by 162.57% to $11.8 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $11.8 million, $3.8 million, and $4.5 million for Q2 2026, Q1 2026, and Q4 2025 respectively.